Gastrointestinal Cancer

Eileen M. O’Reilly, MD, discusses the potential of tumor treating fields for the treatment of patients with locally advanced pancreatic cancer.

Tanios S. Bekaii-Saab, MD, discusses sequencing approaches in metastatic pancreatic cancer and colorectal cancer.

Tanios S. Bekaii-Saab, MD, highlights how HER2-directed agents, chemoimmunotherapy, and biomarker-driven strategies are expanding options for biliary tract cancers.

Rocío García-Carbonero, MD, outlines diagnostic and molecular considerations for poorly differentiated GI neuroendocrine carcinoma.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.

Masatoshi Kudo, MD, PhD, discusses a MAIC evaluating nivolumab/ipilimumab vs durvalumab/tremelimumab and atezolizumab/bevacizumab for unresectable HCC.

Rosario Ligresti, MD, FASGE, discusses the rising incidence of appendix cancer, lack of optimal treatment modalities, and unmet needs for these patients.

Benjamin A. Weinberg, MD, FACP, discusses the potential role of BXCL701 plus pembrolizumab in advanced pancreatic ductal adenocarcinoma.

Perioperative durvalumab sBLA gets priority review in gastric/GEJ cancer, acalabrutinib combination sNDA under review in CLL, and more.

Here is your guide to all therapeutic options that were approved by the FDA in July 2025 spanning tumor types.

Read a recap of the episodes of OncLive On Air that debuted in July 2025.

Can-Fite has reached the over 50% enrollment milestone for an ongoing phase 2a trial evaluating namodenoson in pancreatic cancer.

Drs Moriarity and Webber discuss a study evaluating neoantigen-reactive CISH knockout TIL therapy in patients with metastatic gastrointestinal cancers.

Durvalumab received FDA priority review and breakthrough therapy designation for resectable gastric and GEJ adenocarcinoma.

RP1 BLA in advanced melanoma receives CRL from FDA, generic ibrutinib tablets gets green light for B-cell malignancies, and more.

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss how KRAS(ON) inhibitors differ in mechanism from KRAS(OFF) inhibitors.

VS-7375 earned FDA fast track designation for KRAS G12D–mutant pancreatic ductal adenocarcinoma.

The European Commission has approved cabozantinib for the treatment of patients with pancreatic and extrapancreatic neuroendocrine tumors.

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss the evolving role of KRAS G12C and pan-KRAS inhibitors in pancreatic cancer.

Richard S. Finn, MD, discusses the background of the MORPHEUS-Liver trial of tiragolumab plus atezolizumab and bevacizumab in HCC.

Dr Vogel highlights the importance of the European Commission’s approval of zanidatamab for previously treated, metastatic HER2+ biliary tract cancer.

Samuel J. Klempner, MD, discusses the safety and efficacy of givastomig plus nivolumab and chemotherapy in metastatic gastric cancers.

Benjamin A. Weinberg, MD, FACP, discusses the clinical implications of data with BXCL701 plus pembrolizumab in metastatic pancreatic ductal adenocarcinoma.

Panelists discuss how communication between community oncologists and academic centers is essential for advancing gastrointestinal stromal tumor (GIST) treatment through clinical trial participation, molecular analysis, and the promising future of personalized therapy based on individual tumor mutation profiles.

Tanios S. Bekaii-Saab, MD, discusses current and emerging therapeutic targets for the treatment of patients with biliary tract cancers.